Open an account

Anavex Life Sciences

AVXL · NASDAQ

$1.36+$0.11 (+8.80%)TodayMarket closed ·
Prev close $1.25

AVXL analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $20.40 (+1400.0% upside)

Low
$20.20
Now
$1.36
High
$21.00

Upgrades and downgrades

The latest rating actions, newest first

AVXL analyst upgrades, downgrades and rating actions
FirmDateActionRating
D. Boral CapitalMar 31, 2026MaintainsBuy
D. Boral CapitalMar 26, 2026MaintainsBuy
D. Boral CapitalMar 23, 2026MaintainsBuy
HC Wainwright & Co.Feb 10, 2026MaintainsBuy
D. Boral CapitalFeb 9, 2026MaintainsBuy
D. Boral CapitalJan 6, 2026MaintainsBuy
D. Boral CapitalDec 19, 2025MaintainsBuy
HC Wainwright & Co.Dec 19, 2025MaintainsBuy
D. Boral CapitalDec 15, 2025MaintainsBuy
HC Wainwright & Co.Nov 28, 2025MaintainsBuy

The case for and against

Updated Sep 8, 2026

Bull case

Anavex Life Sciences is well-positioned for growth with a strategic reset in the EU following negative feedback from the EMA, while pursuing ongoing regulatory engagement in the US. They have also submitted additional data to the FDA and are actively working to address CHMP feedback to strengthen their data package. Their multi-indication potential for drugs like ANAVEX 2-73 in markets like Alzheimer's, Rett Syndrome, and Parkinson's Disease Dementia gives them a wide range of possibilities for growth, and their lower probability of success in therapeutic models in the US (50%) and EU (15%) further supports their potential.

Bear case

Anavex Life Sciences is facing a negative outlook due to several factors. The company's pipeline of drugs under development for various CNS diseases has a high risk of failure and limited potential for success. Additionally, the company's financials are not strong, with a high discount rate and low probability of success in its therapeutic models, making it a risky investment. Furthermore, while the company's latest update on correlation analyses and subgroup framing is supportive, it is not a new registrational outcome or regulatory event, highlighting the company's lack of significant progress.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.